Lassa Virus Seroprevalence in Sibirilia Commune, Bougouni District, Southern Mali
Nafomon Sogoba, Kyle Rosenke, Jennifer Adjemian, Sory Ibrahim Diawara, Ousmane Maiga, Moussa Keita, Drissa Konaté, Abdoul Salam Keita, Ibrahim Sissoko, Matt Boisen, Diana Nelson, Darin Oottamasathien, Molly Millett, Robert F. Garry, Luis M. Branco, Sékou F. Traoré, Seydou Doumbia, Heinz Feldmann, and David Safronetz
Author affiliations: University of Sciences, Techniques and Technologies of Bamako, Bamako, Mali (N. Sogoba, S.I. Diawara, O. Maiga, M. Keita, D. Konaté, A.S. Keita, I. Sissoko, S.F. Traoré, S. Doumbia); National Institutes of Health, Hamilton, Montana, USA (K. Rosenke, H. Feldmann, D. Safronetz); National Institutes of Health, Bethesda, Maryland, USA (J. Adjemian); Corgenix Medical Corporation, Inc., Broomfield, Colorado, USA (M. Boisen, D. Nelson, D. Oottamasathien, M. Millett); Tulane School of Medicine, New Orleans, Louisiana, USA (R.F. Garry); Zalgen Labs LLC, Germantown, Maryland, USA (L.M. Branco); Public Health Agency of Canada, Winnipeg, Manitoba, Canada (D. Safronetz)
Main Article
Figure 2
Figure 2. Demographic characteristics of study population in assessment of Lassa virus seroprevalence, southern Mali, 2015. A) Age; B) sex.
Main Article
Page created: March 15, 2016
Page updated: March 15, 2016
Page reviewed: March 15, 2016
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.